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THE EPIDEMICS OF INJECTING DRUG USE
AND BLOOD-BORNE DISEASE:
A PUBLIC HEALTH PERSPECTIVE•
LAWRENCE

0. GoSI'IN••

I. INTRODUCTION

The twin epidemics of injecting drug use and blood-borne disease threaten
both public health and social structure. The drug-related health problems of the
estimated 1.5 million injecting drug users (IDUs) in the United States 1 range
from blood-borne infections to physical deterioration and death. 2 The most
comprehensive longitudinal study among IDUs found staggering seroprevalence
rates for blood-borne diseases: hepatitis C virus (85.3%), hepatitis B virus
(84%), human immunodeficiency virus (24.1 %), and human T-lymphotropic
virus type II (7%). 3

' This paper is part of a national study on the role of syringes and needles in the HIVI AIDS
epidemic undertaken for the U.S. Centers for Disease Control and Prevention, the Carter
Presidential Center, and the Association of Schools of Public Health. The research team for the
project includes: Lawrence 0. Gostin, J.D., LL.D (Hon.) (Principal Investigator); T. Stephen Jones,
M.D., M.P.H., Centers for Disease Control and Prevention; Zita Lazzarini, J.D., M.P.H., Harvard
School of Public Health; and Kathleen Flaherty, J.D., the Georgetown/Johns Hopkins Program on
Law and Public Health. A more extensive version of the matters treated herein is contained in
Lawrence 0. Gostin eta!., Prevention of HWIAIDS Among Injection Drug Users: The Theory and
Science of Public Hea/Jh and Criminal Justice Approaches to Disease Prevention, 46 EMORY L.J.
(forthcoming 1997); Lawrence 0. Gostin eta!., Prevention of HW/AIDS and Other Blood-Borne
Diseases Among Injection Drug Users: A National Survey on the Regulalion ofSyringes and Needles,
277 JAMA 53 (1997); Larry Gostin, The Interconnected Epidemics ofDrug Dependency and AIDS,
26 HARV. C.R.-C.L. L. REv. 113 (1991). James G. Hodge, Jr. and Kathleen Joann Lester, both

of the Georgetown/Johns Hopkins Program on Law and Public Health, made important contributions
in the research of this article.
•• Professor of Law, Georgetown University Law Center; Adjunct Professor of Public Health,
Johns Hopkins University School of Hygiene and Public Health; Co-Director, Georgetown/Johns
Hopkins Program on Law and Public Health.
1. Estimates of IDUs in the United States range from 1.1 to 1.9 million. NATIONAL REsEARCH
COUNCIL, PREVENTING HIV TRANSMISSION: niE ROLE OF STERILE NEEDLES AND BLEACH 58-59
(Jacques Normand et al. eds., 1995) [hereinafter NATIONAL REsEARCH COUNCIL, PREVENTING
HIV]; NATIONAL REsEARCH COUNCIL, AIDS: SEXUAL BEHAVIOR AND INTRAVENOUS DRUG USE
(Charles F. Turner eta!. eds., 1989) [hereinafter NATIONAL REsEARCH COUNCIL, AIDS].
2. Drug-induced deaths exceeded 10,000 persons in 1989, a 58% increase over a nine year
period. See BUREAU OF JUSTICE STATISTICS, U.S. DEP'T OF JUSTICE, A NATIONAL REPORT:
DRUGS, CRIME, AND THE JUSTICE SYSTEM (1992).
3. Richard S. Garfein et al., Viral Infections in Short-Term Injection Drug Users: The
Prevalence of the Hepatitis C, Hepatitis B, Human Immunodeficiency, and Human T-Lymphotropic
Viruses, 86 AM. J. PuB. HEALTH 655 (1996).
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Injecting drug use is the second most frequently reported risk for AIDS. 4
As of October 31, 1995, of the 501 ,310 cases of AIDS reported to the Centers
for Disease Control and Prevention (CDC).~ 184,359 were directly or indirectly
associated6 with injecting drug use. 7 This number represents 36% of all AIDS
cases reported since the beginning of the epidemic. In contrast, in 1981, only
12% of all reported AIDS cases were associated with injecting drug use. 8
These data, together with those showing reductions in HIVI AIDS among men
who have sex with men, 9 suggest that injecting drug use is the engine that is
driving the modem HIV epidemic.
Blood-borne disease in the drug-dependent population disproportionately
strikes the urban poor, African Americans, and Hispanics. Ethnographic studies
describe this population as "street drug abusers," the vast majority of whom are
homeless, unemployed, or underemployed. 10 In addition, many of these
persons suffer from multiple physical dependencies on drugs and alcohol.
Studies suggest that the vulnerability of the drug-dependent person often
compounds her inability to meet her health needs. Minorities, moreover,
generally bear a disproportionately high burden of AIDS cases 11 and IOU-

4. CENTERS FOR DISEASE CONTROL & PREVENTION, U.S. DEP'T OF HEALTH & HUMAN
SERVICES, HIV/AIDS SURVEILLANCE REPORT, 1995, at 5 (1996) [hereinafter HN/AIDS
SURVEILLANCE REPORT].
5. Centers for Disease Control & Prevention, U.S. Dep't of Health & Human Services, First
500,000AIDSCases-United States, 1995,44 MORBIDITY & MORTALITYWKLY. REP. 849 (1995).
6. A direct or indirect association with injecting drug use includes persons who are IDUs
(n= 161,891), their heterosexual sex partners (n= 18,710), and children (n=3758) whose mothers
were IDUs or were sex partners of IDUs. Centers for Disease Control & Prevention, U.S. Dep't
of Health & Human Services, AIDS Associated with Injecting-Drug Use-United States, 1995, 45
MORBIDITY & MORTAUTY WKLY. REP. 392 ( 1996) [hereinafter AIDS Associated with Injecting-Drug
Use].
7. ld.
8. NATIONAL REsEARCH COUNCIL, PREVENTING HN, supra note 1, at 9.
9. See, e.g., Centers for Disease Control & Prevention, Update: Trends in AIDS Among Men
Who Have Sex with Men-United States, 1989-1994, 44 MORBIDITY & MORTALITY WKLv: REP.
401, 403 (1995); Scott D. Holmberg, 1he Estimated Prevalence and Incidence of HN in 96 Large
Metropolitan Areas, 86 AM. I. PuB. HEALTH 642, 645 (1996) ("In almost all cities, there has been
a marked drop in HIV seroprevalence among gay and bisexual men seen at all testing sites in recent
years.").
10. Harvey W. Feldman & Patrick Biernacki, U.S. Dep't of Health & Human Services, 1he
Ethnography ofNeedle Sharing Among Intravenous Drug Users and Implications for Public Policies
and Intervention Strategies, in NEEDLE SHARING AMONG INTRAVENOUS DRUG ABUSERS: NATIONAL
AND INTERNATIONAL PERSPECTIVES 28, 34 (Robert J. Battjes & Roy W. Pickens eds., 1988).
11. Racial and ethnic minorities represent large proportions of newly diagnosed cases of AIDS,
due primarily to injecting drug use. In 1993, 51% of new adult and adolescent male AIDS cases,
75% of new adult and adolescent female AIDS cases, and 84% of new pediatric AIDS cases
occurred among racial and ethnic minorities. See Centers for Disease Control & Prevention, AIDS
Among Racial/Ethnic Minorities-United States, 1993, 43 MORBIDITY & MORTALITY WKLY. REP.
644 (1994).
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associated AIDS cases: 75% of IDU-associated AIDS cases in 1995 occurred
among African Americans (50%), Hispanics (24%), and other ethnic
communitiesY The rate of IDU-associated AIDS per 100,000 population is
3.5 for whites and 50.9 for African Americans, 13 a 14.5-fold difference based
on race alone.
Blood-borne transmission of infectious disease has a cascading effect,
spreading disease from IDUs to women, and from women to children across the
population. Injecting drug users can transmit infection by sharing contaminated
injection and drug preparation equipment, primarily syringes and needles. 14
Persons infected through contaminated syringes may in tum infect their sexual
partners. 15 Pregnant women can transmit infection to their children during
pregnancy, delivery, and breast-feeding. 16
Women in relationships with IDUs face a serious risk of infection. Some
women may be unaware that their partners are IDUs; some women may feel
trapped in abusive, psychologically or economically-dependent relationships; 17
others may engage in sexual relationships for drugs or money. 18 Women in
these relationships may feel powerless to insist that their partner use a
condom. 19 Because these women lack control over their partners' behavior,
they have few options to protect themselves from the risk of blood-borne
infection and sexually transmitted diseases.
Injecting drug use has a catalytic effect on the HIV I AIDS epidemic among
women and newborns. Of the 71,818 AIDS cases among women reported
through December 1995, nearly 65% were IDUs or had sex with an IDU. 20
Further, of the 6256 perinatally-acquired AIDS cases reported through
December 1995, 60% were born to mothers who were IDUs or had sex with an
IDU. 21 These data suggest that drug use-the use of crack among women,

12. AIDS Associatedwith Injecting-Drug Use, supra note 6, at 392.
13. /d. at 396.
14. For a discussion of the mechanism of needle-borne transmission, see infra text
accompanying notes 33-39.
15. NATIONAL REsEARCH COUNCIL, PREVENTING HIV, supra note 1, at 28.
16. /d. at 29-30.
17. See Karen H. Rothenberg & Stephen J. Paskey, 1he Risk ofDomestic Violence and Women
with HN Infection: Implications for Partner Notification, Public Policy, and the Law, 85 AM. J.
PUB. HEALTH 1569, 1570 (1995) {noting high levels of depression, physical abuse, and reported
feelings of powerlessness among women who use injecting drugs).
18. GERRY PEARLBERG, WOMEN, AIDS, & COMMUNmES: A GUIDE FOR AcnON 61-62
{1991).
19. See generally LAWRENCE 0. GOSTIN & ZITA LAZZARINI, HUMAN RIGHTS AND PUBLIC
HEALTH IN THE AIDS PANDEMIC {forthcoming 1997) (on file with author).
20. HIV/AIDS SURVEILLANCE REPORT, supra note 4, at 12-13.
21. /d.
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trading sex for drugs, 22 and needle sharing among heroin, cocaine, and
methamphetamine users-is the most potent stimulus for the modem HIVI AIDS
epidemic. 23 The CDC estimates that approximately. half of the 41,000 new
HIV infections reported annually in the United States are occurring among
IDUs. 24
The dual epidemics of drug use and HIVI AIDS exact a considerable cost
from society. Injecting drug use is estimated to cost $58.3 billion a year in lost
productivity, motor vehicle accidents, crime, stolen property, and drug
treatment. 25 Added to these is the impact of HIVIAIDS. The cost of
providing health care to a person living with HIVI AIDS, discounted to
determine the present value of future costs, is estimated to be between $56,000
and $80,000, 26 a figure that' is somewhat lower than earlier, non-discounted
estimates. 27 Although these data significantly underestimate the current lifetime
health care costs of HIVIAIDS, they indicate that the population living with
HIVI AIDS incurs substantial expenditures. When the conservative lifetime
health care costs of persons living with HIVI AIDS are multiplied by the
estimated 20,500 new HIV cases each year associated with injecting drug use, 28
the total annual expenditure ranges from $1.15 billion to $1.64 billion. More
important, since HIVI AIDS primarily affects people during their prime work and
child-rearing years, the cost of health care does not reflect the overall societal
cost of losing productive workers and primary caretakers of minor or elderly
dependents.

22. Women who use crack, whether or not they inject drugs or trade sex for drugs, are at an
increased risk of becoming infected because of increased sexual activity and loss of inhibitions
brought on by the use of crack cocaine. D. Paone eta!., Sex, Drugs, and Syringe Exchange in New
York City: Women's Experiences, 50 J. AM. WOMEN'S MED. Ass'N 109, 112 (1995) (reporting that
30% of female IDUs interviewed (n=907) reported engaging in commercial sex work); NATIONAL
COMMISSION ON AIDS, THE TwiN EPIDEMICS OF SUBSfANCE USE AND HIV 6 (1991) (quoting a
crack dealer who reported trading drugs for sex with 30 different women in the course of one
month).
23. NATIONAL REsEARCH COUNCIL, PREVENTING HIV, supra note I, at 10 ("The
epidemiologic data do indicate that the HIV epidemic in this country is now clearly driven by
infections occurring in the population of injection drug users, their sexual partners, and their
offspring.").
24. Holmberg, supra note 9, at 642.
25. Dorothy P. Rice et al., Estimates ofEconomic Costs of Alcohol and Drug Abuse and Mental
Illness, I985 and 1988, 106 PUB. HEALTH REP. 280, 285 (1991).
26. M.E. Guinan et al., Estimating the Value of Preventing a Human Immunodeficiency Virus
Infection, 10 AM. J. PREVENTIVE MED. I (1994).
27. Fred J. Hellinger, The Lifetime Cost of Treating a Person with HIV, 270 JAMA 474, 474
(1993).
28. See Holmberg, supra note 9, at 642 (roughly half of the 41,000 new HIV infections each
year occur among IDUs).
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The interconnected epidemics of blood-borne infection and injection drug
use sap society of productive resources, in lost workers, broken families, and
costly health care and social services. These economic and social burdens
provide a compelling justification for a public health approach to injecting drug
use. A public health approach does not require society to abandon criminal
penalties for illicit drug use. However, it does require implementation of public
health policies that are known to work based on sound scientific studies. Public
health research has demonstrated that blood-borne disease among IDUs and their
sexual partners is, to a significant extent, preventable. Data exist to demonstrate
that implementation of well-established public health programs could markedly
reduce morbidity and mortality without undermining criminal justice objectives.
In this Article, I first examine the mechanism by which blood-borne disease
is transmitted through sharing of injection equipment. Thereafter, I present a
public health strategy for reducing multi-person use of contaminated injection
equipment. This strategy includes: repealing or modifying current laws and
regulations making possession and distribution of sterile injection equipment a
criminal offense; implementing syringe exchange programs to expand access to
new syringes for users of injection drugs; and counseling, education, and
treatment targeted to IDUs, including those in the prison and health care system.
The objective of a public health approach is not to encourage or enable IDUs to
obtain and use drugs; public health strategies actively seek to reduce drug use
due to its profound adverse effects on physical and mental health. Rather, the
public health approach seeks to substantially improve health outcomes for IDUs
who cannot or will not stop using drugs.
II. THE PuBLIC HEALTH EFFECTS OF LIMITING THE SUPPLY OF
STERILE DRUG INJECTION EQUIPMENT:
THE MULTI-PERSON USE OF SYRINGES AMONG IDUS
The primary mode of HIV transmission among IDUs is through multiperson use, often called "sharing," of drug injection equipment. 29 The term
"sharing," used in the epidemiologic and ethnographic literature, 30 does not
accurately reflect the motive or the meaning that IDUs ascribe to this

29. NATIONAL REsEARCH COUNCIL, PREVENTING HIV, supra note 1, at 24.
30. /d. at 24-25. See also NATIONAL REsEARCH COUNCIL, AIDS, supra note 1, at 189; James
A. Inciardi & J. Bryan Page, Drug Sharing Among Intravenous Drug Users, 5 J. ACQUIRED IMMUNE
DEFICIENCY SYNDROME & HUM. RETROVIROLOGY 772 {1991); Donald C. DesJarlais ct al., AIDS
and Needle Sharing Within theN Drug Use Subculture, in THE SOCIAL DIMENSIONS OF AIDS:
METHOD & THEORY 111 (Douglas A. Feldman & Thomas M. Johnson eds., 1986).
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behavior. 31 The word "sharing" implies that the transfer of syringes and
needles among IDUs is a voluntary act of altruism and social connection. 32
Research indicates, however, that sharing is often a pragmatic response to
syringe scarcity. This section details the mechanism for the spread of infection
through multi-person syringe use, describes the motivations for transfer of
syringes among partners or groups, and explicates the legitimate medical
purposes behind a policy advocating access to sterile syringes.
A. Mechanism of Blood-Borne Transmission

Multi-person use of drug injection equipment among IOUs is a highly
efficient vector for transmitting blood-borne disease. 33 The behavior. and
motivations for sharing injection equipment are complex, and offer multiple
opportunities for contamination. Each of the behaviors reported by IOUs poses
separate and cumulative risks of transmitting infection among partners or groups
who inject drugs.
The process of injecting drugs involves a number of steps. The first step
is "registering," in which the IOU inserts a needle into a vein in her skin, and
to identify proper placement, withdraws the plunger of the syringe to observe
for the presence of blood in the barrel of the syringe. 34 The IOU then injects
the drug. The next step is "booting:" while the needle remains in the vein, the
IOU "draws back on the plunger of the syringe to fill the barrel with blood and
then reinjects the blood, sometimes repeating this practice several times. " 35
"Booting" ensures that the drug solution is fully discharged from the syringe,
and increases the "high," particularly when injecting cocaine. During the
injection process, the needle, hub, barrel, and plunger of the syringe all become
contaminated with blood.
When the injection is complete, the drug
paraphernalia-including the "cooker" and "cotton" -are frequently soaked in

31. StephenK. Koester, Copping, Running and Paraphernalia Laws: Contextual Variables and
Needle Risk Behavior Among Injection Drug Users in Denver, 53 HUM. ORG. 287, 289 (1994).
Injecting drug users themselves often do not consider the multi-person use of syringes as "sharing."
When asked if they "share" syringes, they often answer "no," but when asked if they allow others
to use their syringe, they respond, "yes." /d.
32. Robert G. Carlson et al., Ethnography, Epidemiology and Public Policy: Needle Use
Practices and Risk Reduction Among IV Drug Uurs in the Midwest, in ANTHROPOLOGY AND
GLOBAL AIDS POUCY (Douglas A. Feldman ed., forthcomin& 1997).
33. Gerald H. Friedland & Robert S. Klein, Transmission of the Human Immunodeficiency
Virus, 317 NEW ENG. J. MED. 1125, 1125 (1987).
34. NATIONAL REsEARCH COUNOL, PREVENTING HIV supra note 1, at 25.
35. /d.
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the same "rinse water. " 36 The IOU may then transfer the "works" (the entire
set of drug preparation and injection equipment) to the next IOU, who, in reusing the equipment, injects the previous user's blood residue directly into his
vein. The method transmits into the current user any blood-borne pathogens
carried by the previous user. The more the IOU "mixes" the equipment with
others, and the more often he or she injects with contaminated syringes, the
greater the risk of infection.
Injecting drug users share works with sexual partners, friends, or strangers.
When IDUs are unable to obtain sterile syringes and needles from pharmacists,
health care professionals, or public health departments, they procure their
equipment from street sellers and "shooting galleries. " 37 Shooting galleries are
locations where IDUs congregate to inject drugs, often sharing works; these
galleries are typically situated near a "copping place," an area where drugs can
be purchased. On occasion, syringes are included with the drug purchase, or
are rented or lent by dealers ("house works"). Syringes tend to be transferred
anonymously when selected from a common stock in a shooting gallery (a
process called "pooling") or when discovered after another IOU has "stashed"
them for later use. 38 Drug injection equipment may be used in this way until
the needle becomes occluded with blood, is too dull to use, or breaks. 39
Shooting galleries and house works are particularly detrimental to the public
health because they involve sharing beyond a discrete group of friends or sexual
partners.
B. Sharing Drug Injection Equipment: Syringe Scarcity as a Rationale for IDU
Behavior

Although multi-person use of syringes is quite complex, it is possible to

36. /d. at 26-27. The "cooker" is a small container, frequently a bottle-cap or spoon, used to
dissolve the drug, which often is in powder form. /d. The "cotton" strains undissolved impurities
from the solution prepared in the cooker as the drug is drawn up into the syringe. /d. The "rinse
water" is used to rinse out syringes and needles before they are reused-not necessarily to
decontaminate the equipment-but to prevent clotting and therefore unusable works. /d. at 28.
37. See Dale D. Chitwood et al., HJV Seropositivity ofNeedles from Shooting Galleries in South
Florida, 80 AM. I. PUB. HEALTII 150 (1990).
38. Koester, supra note 31, at 289. See also Bryan I. Page et al., Intravenous Drug Use and
HJV lnfedion in Miami, 4 MED. ANTHROPOLOGY Q. 56 (1990).
39. Donald C. Des Iarlais et al., U.S. Dep'tofHealth.& Human Services, The Sharing ofDrug
lnjedion Equipment and the AIDS Epidemic in New York City, in NEEDLE SHARING AMONG
INTRAVENOUS DRUG ABUSERS: NATIONAL AND INTERNATIONAL PERSPEcnVES 164 (Roben I.
Battjes & Roy W. Pickens eds., 1988); Anthony Hopkins, U.S. Dep't of Health & Human Services,
Needle Sharing and Street Behavior in Response to AIDS in New York City, in NEEDLE SHARING
AMONG INTRAVENOUS DRUG ABUSERS: NATIONAL AND INTERNATIONAL PERSPEcnVES 18, 24
(Roben I. Battjes & Ray W. Pickens eds., 1988) (discussing a study in which some users reponed
using the same drug injection equipment more than 20 times).
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ascertain what motivates IDUs to re-use equipment. When the issue was first
studied, some researchers attributed "sharing" of drug injection equipment in
part to the drug subculture and its unfathomable routines; IDUs were thought to
transfer their drug preparation and injection equipment as a social convention or
as a means of communal reinforcement. 40 Increasingly, however, researchers
have identified a scarcity of sterile injection equipment-rather than a culturallycreated norm-as a leading factor in many IDUs' use of contaminated
equipment.
When asked, IDUs express a preference for new syringes and needles, and
cite compelling reasons: the risk of blood-borne infection witnessed among their
friends and partners; used plungers are ineffective; used needles are blunt and
clog easily; and new needles are easier to insert, particularly for IDUs who are
"hard to hit" or who want to protect their remaining "good veins. " 41 Injecting
drug users, moreover, perceive the possession of drug paraphernalia as
significantly increasing the possibility of detection by law enforcement. 42
Unlike small quantities of drugs, syringes are difficult to hide or discard. The
IDU's reluctance to possess syringes means that he must borrow them when he
injects, creating the very risk of blood-borne infection that public health seeks·
to prevent. When IDUs experience a psychological or physiological craving for
the drug, they are likely to use whatever works are readily available. 43 It is
essential, therefore, that sterile syringes are easily accessible at the time of
injection so the IDU does not borrow, share, or pool injection equipment.

C. The Legitimate Medical Purpose of Sterile Syringes
Decontamination efforts, such as flushing drug equipment with bleach, can
reduce the risk of exposure, but are not as safe as using a new, sterile syringe
for each injection. 44 Limiting the circumstances in which IDUs are likely to
re-use equipment lowers the probability of spreading disease. Consequently,
experts in preventive medicine and public health advise IDUs to utilize new
sterile equipment for each injection. 45

40. See John L. Black eta!., Sharing of Needles Among Users of Intravenous Drugs, 314 NEW
ENG. J. MED. 446 (1986); David D. Celentano et al., Risk Factors for Shooting Gallery Use and
Cessation Among Intravenous Drug Users, 81 AM. J. PUB. HEALTII 1291 (1991).
41. Koester, supra note 31, at 289.
42. Id. at 291; Alice A. Gleghorn et a!., Acquisition and Use of Needles and Syringes by
Injecting Drug Users in Baltimore, Maryland, 10 I. ACQUIRED IMMUNE DEFICIENCY SYNDROME &
HUM. REfROVIROLOGY 97, 99 (1995).
43. R. T. D 'Aquilla & A.B. Williams, Epidemic Human Immunodeficiency Virus (HIV) Infection
Among Intravenous Drug Users, YALE J. BIOLOGY & MED. 535, 545 (1987).
44. H.W. Haverkos & T.S. Jones, HTV, Drug-Use Paraphernalia, and Bleach, 7 I. ACQUIRED
IMMUNE DEFICIENCY SYNDROME 741 (1994).
45. Id.
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Unlike other drug paraphernalia, sterile syringes serve important clinical
and public health functions (e.g., preventing the transmission of HIV infection
and other blood-borne diseases among IDUs, their sex partners, and their
children). A legitimate medical and public health purpose exists for increasing
IDUs' access to sterile syringes. In summary, the medical and public health
communities attribute a scientific and social meaning to syringes that contrasts
sharply with the criminal justice view of syringes as instruments of illicit drug
use and its attendant moral decay. Below, I examine three public health policies
to reduce the adverse health effects of drug injection: repeal of laws and
regulations restricting access to sterile injection equipment; establishment of
syringe exchange programs; and counseling, education and treatment.
III. REPEAL OF LAWS AND REGULATIONS RESTRICTING ACCESS TO
STERILE INJECTION EQUIPMENT

Broadly speaking, four categories of law and regulation directly restrict the
supply of sterile drug injection equipment: syringe prescription laws, drug
paraphernalia laws, the Federal Mail Order Drug Paraphernalia Control Act, and
pharmacy regulations and practice guidelines. This section describes these laws
and regulations and assesses their effects on the population's health. 46
A. Syringe Prescription Laws

Syringe prescription laws proscribe the dispensing or possession of a
syringe without a valid medical prescription. Syringe prescription laws do not
have a criminal intent requirement. Thus, in a state with a syringe prescription
law, a pharmacist who dispenses a hypodermic syringe without a prescription
need not know that the buyer intends to use the syringe to inject illegal drugs;
the very act of selling or dispensing the syringe without a prescription constitutes
a violation.
Eight states and one territory have syringe prescription statutes prohibiting
the dispensing of hypodermic needles and syringes without a valid medical
prescription. 47 Six additional states restrict the purchase of syringes without
a prescription. These laws variously require prescriptions for sales to specific

46. The data presented in this section are taken from a national survey undertaken under the
auspices of the Centers for Disease Control and Prevention and the Association of Schools of Public
Health. The methodology and complete data are reported in Lawrence 0. Gostin et al., Prevention
of HIVIAIDS Among Injection Drug Users: The Theory and Science of Public Health and Criminal
Justice Approaches to Disease Prevention, 46 EMORY L.J. (forthcoming 1997).
47. California, Delaware, Ulinois, Massachusetts, New Hampshire, New Jersey, New York,
Rhode Island, and the Virgin Islands.
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classes of purchasers (e.g., minors), 48 for certain types of purchases (e.g.,
bulk), 49 or for non-authorized purposes. 50
To limit physicians' and pharmacists' discretion in dispensing syringes,
most syringe prescription laws require a "legitimate medical purpose." The
"legitimate medical purposes" doctrine strengthens the regulatory effect of
syringe prescription laws through dual mechanisms. First, the doctrine holds that
a prescription is invalid unless it has been issued in good faith for a therapeutic
purpose. Physicians have been convicted or have had their licenses revoked for
improperly prescribing drugs or drug paraphernalia. 51 Secondly, the laws in
many states require pharmacists to document syringe and needle sales, together
with the intended medical purpose. Under these laws, persons charged with
illegal possession of a hypodermic syringe or needle bear the burden of proving
that they have sufficient authority or license to possess such equipment. 52
B. Drug Paraphernalia Laws

Throughout the 1960s and 1970s, against the backdrop of concern about
illegal drugs and the realization that traditional anti-drug laws were inadequate
to curb drug use, states and municipalities enacted drug paraphernalia laws.
Many legislatures drafted broadly worded statutes that would comprehensively
cover various drug paraphernalia. The courts found these early drug
paraphernalia laws to be unconstitutionally vague and overly broad. 53 To cure
the constitutional flaws, in 1979 the Drug Enforcement Administration
promulgated the Model Drug Paraphernalia Act (MDPA). 54 Moreover, the
Supreme Court advanced the trend toward comprehensive drug paraphernalia
laws by upholding the constitutionality of broadly worded local laws that were
not based upon the MDPA. 55

48. Virginia requires a prescription for sale to individuals under age 16; Florida requires one
for sale to individuals under age 18; Oregon requires the authorization of a physician, parent,
guardian, or other acceptable means for sale to minors; and Maine specifies that anyone over the
age of 18 may purchase from an authorized seller.
49. A 1992 amendment to Connecticut law requires a prescription only for sales of more than
ten syringes.
50. In Nevada, hypodermic devices may be sold without a prescription for medical, veterinary,
industrial, and hobby purposes, as long as the seller is satisfied that the device will be used lawfully.
51. Minnesota ex rei. Whipple v. Martinson, 256 U.S. 41 (1921).
52. Commonwealth v. Jefferson, 387 N.E.2d 579, 581 (Mass. 1979).
53. See, e.g., Geiger v. City of Eagan, 618 F.2d 26 (8th Cir. 1980) (declaring a local
ordinance banning the possession, sale, or transfer of a "drug related device" as unconstitutionally
vague).
54. Drug Paraphernalia: Hearing Before the House Select Comm. on Narcotics Abuse &
Control, 96th Cong., 1st Sess. 6 (1979) (statement of Sue Rusche).
55. Village of Hoffman Estates v. Flipside, Hoffman Estates, Inc., 455 U.S. 489 (1982).
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Forty-seven states, the District of Columbia, and the Virgin Islands have
enacted drug paraphernalia laws; only Alaska, Iowa, 56 South Carolina, and four
territories57 have no state or territory-wide drug paraphernalia statute. In fortysix states and territories, the drug paraphernalia laws are based at least partially
on the MDPA. The statutes often enumerate the objects regarded as drug
paraphernalia, and almost always include "[h]ypodermic syringes, needles, and
other objects used, intended for use, and designed for use in parenterally
injecting controlled substances into the human body. "58
Drug paraphernalia statutes ban the manufacture, sale, distribution,
possession, or advertising of a wide range of devices if knowledge exists that
they may be used to introduce illicit substances into the body. 59 The statute is
not violated if the drug injection equipment is sold without knowledge that it will
be used to inject illegal drugs. Thus, a pharmacist who sells hypodermic
syringes and needles over-the-counter, believing that the purchaser is an insulindependent diabetic, commits no offense under drug paraphernalia laws.
C. The Federal Mail Order Drug Paraphernalia Control Act
The Federal Mail Order Drug Paraphernalia Control Act (Mail Order Act),
enacted as part of the Anti-Drug Abuse Act of 1986, was expanded in 1990. 60
The Mail Order Act was originally designed to prohibit the use of the United
States Postal Service in transporting equipment intended for drug consumption.
The statute was amended to proscribe any offer for sale and transportation in
interstate or foreign commerce, or import or export of drug paraphernalia. 61
In addition, the Act authorizes seizure and forfeiture of drug paraphernalia. 62
Although challenged as unconstitutionally vague, and as .lacking an intent
requirement, the Mail Order Act has been upheld on both counts. 63

56. Alaska and Iowa have local drug paraphernalia provisions covering some counties and
cities.
57. Guam, Northern Mariana Islands, Puerto Rico, and American Samoa.
58. See, e.g., NEB. REV. STAT. § 28-439(3) (1996).
59. MODEL DRUG PARAPHERNALIA Acr art. II (1979), reprinted in Gregory R. Veal, Note,
The Model Drug Paraphernalia Act: Can We Outlaw Head Shops-And Should We?, 16 GA. L.
REv. 137 (1981).
60. 21 U.S.C. § 857 (1986) (repealed in 1990 and re-enacted as 21 U.S.C. § 863 (1996)).
61. 21 U.S.C. § 863(a)(l)-(3).
62. 21 U.S.C. § 863(c).
63. See generaUy Theresa A. Kleine-Kracht, Note, Resolving Statutory Ambiguity with a Split
Scienter Approach: The Second Circuit's Approach to the Federal Mail Order Drug Paraphernalia
Act, 81 KY. L.J. 779 (1992-1993).
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The Mail Order Act is notable in that it conferred federal jurisdiction over
an area traditionally reserved for the states. 64 Police and prosecutors, in
deference to local public health authorities, may choose to relax enforcement of
state laws that restrict access to drug injection equipment. Such a decision,
however, does not preclude federal authorities from vigorously enforcing the
Mail Order Act.
D. Pharmacy Regulations and Practice Guidelines
Pharmacy regulations are established pursuant to state law by Pharmacy
Boards or other governmental agencies, such as the Department of Consumer
Protection, the Department of Health, or the Department of Drug Control.
Pharmacists are legally required to comply with the rules regulating the sale of
syringes. In addition, state pharmacy boards typically establish practice
guidelines. Although these guidelines lack the force of law, a pharmacist who
fails to comply with them could be found civilly liable under state tort law or
be subjected to professional sanction.
Thirty-two jurisdictions have pharmacy regulations or practice guidelines
restricting access to syringes. 65 Twenty-three of these states do not have
syringe prescription laws. 66 In at least thirteen of these twenty-three states,
regulations or mandatory practice standards effectively bar IDUs and the general
public from purchasing syringes. 67 The regulations require that sellers ask
purchasers to proffer some form of identification, along with a prescription or
other proof of medical need. These rules may also impose record-keeping
requirements.
Other states specify that purchasers must produce valid
identification, such as a driver's license. 68 In many states, pharmacists are
expressly authorized to refuse to sell syringes which they believe may be
intended for illegal use. 69

64. Chris B. Pascal, U.S. Dep't of Health & Human Services, Intravenous Drug Abuse and
AIDS Transmission: Federal and State Laws Regulating Needle Availability, in NEEDLE SHARING
AMONG INTRAVENOUS DRUG ABUSERS: NATIONAL AND INTERNATIONAL PERSPECfiVE 119 (Robert
J. Battjes & Roy W. Pickens eds., 1988). See also supra note 10.
65. Alabama, Arkansas, California, Delaware, District of Columbia, Georgia, Hawaii, lllinois,
Indiana, Kentucky, Maryland, Massachusetts, Minnesota, Missouri, Nevada, New Hampshire, New
Jersey, New Mexico, New York, North Dakota, Ohio, Pennsylvania, Rhode Island, South Carolina,
Tennessee, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming, and the Virgin
Islands.
66. Alabama, Arkansas, District of Columbia, Georgia, Hawaii, Indiana, Kentucky, Maryland,
Minnesota, Missouri, Nevada, New Mexico, Nonh Dakota, Ohio, Pennsylvania, South Carolina,
Tennessee, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.
67. Arkansas, District of Columbia, Georgia, Indiana, Kentucky, Maryland, Nevada, Ohio,
Pennsylvania, Tennessee, Virginia, Washington, and West Virginia.
68. E.g., South Carolina and Virginia.
69. E.g., Georgia, Maryland, Mississippi, Pennsylvania, Tennessee, Texas, and Washington.
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Eighteen jurisdictions track the sale of needles and syringes by requiring
pharmacists to maintain detailed records. 70 The information requested often
includes the purchaser's name and address, the date and quantity of the sale, and
the intended use. Purchasers may also be required to sign a register. In
addition, pharmacists must usually retain the records for a period of time
prescribed in the regulations and, if requested, submit the documents for
inspection by law enforcement or by other government agencies.
In summary, a pervasive network of laws, regulations, and practice
guidelines exist that severely restrict the sale and possession of sterile drug
injection equipment. Every state and the District of Columbia have enacted state
or local laws restricting the sale, distribution, or possess~on of syringes. 71
Forty-nine states, the District of Columbia, and the Virgin Islands have passed
drug paraphernalia statutes or local ordinances. Only South Carolina and four
territories 72 do not have drug paraphernalia provisions. Ten states and one
territory have statutes, regulations, or local ordinances that require a prescription
for the purchase of syringes. 73 Fourteen additional states have regulations or
local ordinances that otherwise limit the sale and purchase of syringes. 74

E. Public Health Effects of Syringe Deregulation
This section examines the public health effects of syringe deregulation. The
principal issue is whether deregulating syringe sale and possession will likely
reduce blood-borne infection without increasing drug use in the population.
1. Over-the-Counter Sale of Syringes: The Role of Pharmacists
Pharmacists face daunting legal and professional hurdles in selling injection
equipment to IDUs. By requiring prescriptions or proof of medical need,
identification, and record-keeping, states impede pharmacists and customers
from instituting safer means for drug injection. Drug users, wary of legal
consequences, may avoid pharmacies out of fear of intrusive questioning and/or
government scrutiny of their purchase records. Pharmacists, wary of criminal

70. Arkansas, California, Connecticut, District of Columbia, lllinois, Indiana, Kentucky,
Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Rhode Island, South
Carolina, Virginia, West Virginia, and the Virgin Islands.
71. Only four territories-Guam, the Northern Mariana Islands, Puerto Rico, and American
Samoa-did not report any restrictions.
72. Guam, Northern Mariana Islands, Puerto Rico, and American Samoa.
73. California, Delaware, Florida, Illinois, Massachusetts, New Hampshire, New Jersey, New
York, Pennsylvania, Rhode Island, and the Virgin Islands.
74. Arkansas, District of Columbia, Georgia, Indiana, Kentucky, Maryland, Michigan, Nevada,
Ohio, South Carolina, Tennessee, Virginia, Washington, and West Virginia.
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prohibitions and professional sanctions, may decline to sell syringes to suspected
IDUs.
Nationwide, pharmacists retain considerable discretion in deciding whether
to sell syringes, and to whom. Some pharmacists sell to all buyers; others
refuse to sell to purchasers who demonstrate visible signs of injection drug use
or who cannot offer a plausible medical justification; still others refuse sales for
discriminatory or capricious reasons. 75 Pharmacist discretion yields wide
variation in the willingness to sell to IDUs. 76 Biases toward, for example,
racial minorities, young people, and homeless or mentally ill persons potentially
limit opportunities for pharmacy customers to purchase hypodermic needles and
syringes. 77
2. Drug User Compliance with Public Health Advice: The Law's Chilling
Effect
The simple act of following public health advice to obtain and use a sterile
syringe for each injection78 can pose acute legal problems for IDUs, including
prosecution for possession of drug injection equipment. An IOU is unlikely to
present a valid medical reason for requiring a syringe and needle, and thus is
likely to violate both syringe prescription and drug paraphernalia laws. Drug
users may be arrested for carrying syringes and even bottles of bleach. 79
One might ask: why would the potential legal consequences of carrying
sterile injection equipment dissuade a drug user, when she is already engaged
in far more serious criminal behavior? From the drug user's perspective, laws
that proscribe the possession of syringes are problematic for a number of
reasons. First, drug users who are· arrested on a drug paraphernalia charge are
subject to fmes and possible incarceration. Secondly, the violation itself marks
the person as a drug user, and may subject her to more intense police
surveillance. Third, once an individual is found to possess drug paraphernalia,

75. A. Glantz eta!., Role of Commun.ily PhaT11Ulcies in Prevention of AIDS Among Injecting
Drug Misusers: Findings ofa Survey in England and Wales, 299 BRIT. MED.J. 1076 (1989); Gerry
V. Stimson, Syringe-Exchange Programmes for Injecting Drug Users, 3 AIDS 253, 254 (1989).
76. R. Ettelson, Sell Needles and Syringes toN Drug Abusers?, 57 PHARMACY nMES 107
(1991).
77. WilliamM. Compton ill eta!., Legal Needle Buying in St. Louis, 82 AM.J. PuB. HEALTII
595 ( 1992); William A. Zellmer, PhaT1Tiilcist Involvement in Needle Exchange Programs, NS34 AM.
PHARMACY 48 (1994) (surveying state pharmacy leaders' attitudes toward over-the-counter sales of
syringes to IDUs and reporting the influence of a strong professional anti-drug bias).
78. GUIDE TO CUNICAL PREVENTIVE SERVICES: REPORT OF THE U.S. PREVENTIVE SERVICES
TASK FORCE (2d ed. 1996) [hereinafter GUIDE TO CUNICAL PREVENTIVE SERVICES].
79. Jeff Stryker, N Drug Use and AIDS: Public Policy and Dirty Needles, 14 J. HEALTil POL.
POL'Y & L. 719, 728 (1989).
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she is more likely to undergo a police search for illicit drugs. Discovery of a
syringe or even bleach may provide probable cause under the Fourth
Amendment to conduct a broader search of the drug user and her possessions,
leading to confiscation of illicit drugs and prosecution for sale or use.
Ethnographic studies vividly illustrate that drug users, fearing detection of
drug injection equipment under these laws, often fail to carry sterile syringes
and needles. 80 Syringe laws and regulations, therefore, create a marked
disincentive for drug users to possess sterile syringes when they purchase or
inject drugs. Ironically, this is precisely the time when users most need sterile
injection equipment. To arrest and prosecute the drug user for complying with
the health department's safer injection practice recommendations effectively
undermines public health.
3. Providing the Means for IDUs to Engage in Safer Drug Injection: Research
Evaluations of Syringe Deregulation
Earlier thinking held that IDUs were engaged in such high risk and criminal
activity that they harbored no concern for their health and well-being, and that
they would refuse to alter their behavior. 81 Some individuals asserted that
cessation of drug use, not harm reduction, was the only way to avoid risk. 82
Yet, numerous studies have shown significant reductions in the frequency of
injection and needle sharing following public health intervention programs that
provide education, counseling, and the means to change high-risk behavior. 83
· Behavioral scientists have consistently observed that education, counseling,
and outreach activities will not modify IDUs' behavior unless they are given the
means to comply with public health advice. 84 One way to provide such means

80. Koester, supra note 31, at 290-91; Feldman & Biernacki, supra note 10, at 32.
81. Alan A. Wartenberg, 'Into Whatever Houses I Enter': HN and Injecting Drug Use, 271
IAMA 151, 151 (1994).
82. See OFFICE OF NATIONAL DRUG CONTROL POLICY, NEEDLE EXCHANGE PROGRAMS: ARE
THEY EFFECTIVE (ONDCP Bulletin No.7, 1992).
83. See, e.g., Donald C. DesJarlais & Samuel R. Friedman, The Psychology of Preventing
AIDS Among Intravenous Drug Users: A Social Learning Conceptualization, 43 AM. PSYCHOL. 865
(1988); Richard C. Stephens et al., Effects of an Intervention Program on AIDS-Related Drug and
Needle Behavior Among Intravenous Drug Users, 81 AM. I. Pus. HEALTH 568, 568-69 (1991).
84. Donald C. DesJarlais & Samuel R. Friedman, HN and Intravenous Drug Use, 2 AIDS
S65, 570-71 (1988). When counseled through educational programs, IDUs will seek to use sterile
syringes; restricting access to syringes creates an artificial scarcity which in tum inflates the street
value. No amount of education is likely to prevent an addict in the throes of withdrawal from using
dirty equipment if that is all that is available. D' Aquilla & Williams, supra note 43, at 553.
Furthertnore, some dealers reportedly repackage used works and sell them as new, a danger most
addicts are ill-equipped to detect. Don C. Des Jarlais & William Hopkins, "Free" Needles for
Intravenous Drug Users At Risk for AIDS: Current Developments in New York City, 313 NEW ENG.
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is to permit IDUs to purchase syringes over-the-counter in pharmacies. Some
states have recently reformed their laws to permit over-the-counter syringe sales,
providing an opportunity to scientifically investigate the health effects. The
results suggest that repealing or modifying restrictive laws may reduce unsafe
injection behavior among IDUs, including re-use of contaminated equipment and
reliance upon questionable sources (e.g., drug dealers, street sellers, and
shooting galleries) for "new" syringes. 85 In Connecticut, where restrictive
laws regarding access to syringes were partially repealed in 1992, evaluation of
the law's impact after one year demonstrated positive behavioral and health
outcomes. In a survey of pharmacies, researchers found that in the year after
non-prescription sales in pharmacies became legal, more than 80% of
pharmacies in the state were making non-prescription sales. 86 Sales of syringes
in areas with large IDU populations increased substantially, suggesting that new
purchasers, including IDUs, were taking advantage of the recently enacted
legislation. 87 Surveys of IDUs in Connecticut also revealed reductions in
unsafe injection practices. Following the change in the law, IDUs reported a
39% drop in multi-person use of syringes. Injecting drug users also reported
a shift in their primary source of syringes-from purchases on the street (of
potentially non-sterile syringes) to purchases from pharmacies (of sterile
syringes). 88
Legal penalties for possession of syringes have failed to solve the problem
of drug abuse and have created an environment in which sterile syringes are
scarce, and risky behavior among IDUs is prevalent. With a limited supply of
syringes and continuing demand, used syringes are sometimes re-packaged and
sold as new. 89 Even when addicts can obtain sterile syringes, the public policy
criminalizing the possession of hypodermic syringes prevents many addicts from
carrying their own injection equipment for fear of arrest. Compelling empirical
data suggest that the prevailing policy promotes multi-person use of injection
equipment, including the renting of syringes in shooting galleries, or the

J. OF MED. 1476, 1476 (1985) [hereinafter DesJarlais & Hopkins, "Free" Needles].
85. Elaine O'Keefe, Altering Public Policy on Needle Exchange: lhe Connecticut Experience,
6 AIDS & PUB. POL'Y J. 159 (1991); Merrill Singer et al., Needle Access as an AIDS Prevention
Strategy for IV Drug Users: A Research Perspective, 50 HUM. ORG. 142 (1991).
86. Linda A. Valleroy et al., Impact of Increased Legal Access to Needles and Syringes on

Community Pharmacies' Needle and Syringe Sales-Connecticut, 1992-1993,

10

J.

ACQUIRED

IMMUNE DEACIENCY SYNDROME & HUM. RETROVIROLOGY 73 (1995).
87. ld.
88. Samuel L. Groseclose et al., Impact of Increased Legal Access to Needles and Syringes on
Practices of Injecting-Drug Users and Police Officers-Connecticut, 1992-1993, 10 J. ACQUIRED
IMMUNE DEFICIENCY SYNDROME & HUM. RETROVIROLOGY 82 (1995).
89. See DesJarlais & Hopkins, "Free" Needles, supra note 84.
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purchase of syringes from street suppliers. 90 During a survey in California,
an ethnographer asked a female heroin addict why she did not carry sterile
syringes to use when she injected drugs: "'Because,' she answered, 'I would
rather get AIDS than go to jail. '" 91
IV.

PuBLIC HEALTH EFFECTS OF SYRINGE EXCHANGE PROGRAMS

Syringe exchange programs (SEPs) provide an organized method of
channeling access to sterile injection equipment. Characteristically, SEPs offer
new syringes and needles to ID Us in exchange for used equipment. Syringe
exchange programs are typically operated or funded by public health
departments, by community-based organizations, or by former IDUs. An April,
1995 survey of sixty SEPs in North America found them operating in forty-six
cities in twenty-one states. 92 During 1994, the SEPs exchanged approximately
eight million sterile syringes for used syringes. 93 In addition, the programs
offered a wide range of services, including instruction on hygienic drug
injection, provision of latex condoms, HIV counseling and testing, tuberculin
skin testing, directly observed tuberculosis therapy, and primary health care. 94
A. The Lawfulness of Syringe Exchange Programs
The lawfulness of SEPs in many jurisdictions is fraught with doubt.
Syringe exchange programs in the April, 1995 survey reported: 55% were
"legal" because they operated in a state with no syringe prescription law or
under an exemption to the state prescription law allowing the SEP to operate;
approximately 32% were "illegal-but-tolerated" because the program operated
in a state with a prescription law but had received a formal vote of support or
approval from a local elected body such as a city council; and 13% were
"illegal/underground" because the program operated in a state with a
prescription law and had no formal support from local elected officials. 95 A
more recent study of fifty-two syringe exchange programs revealed: 25%
operated under claims of lawfulness (none of which had been judicially
reviewed) based upon a local interpretation of state drug or public health
statutes; 52% had received formal authorization under state drug paraphernalia

90. Jean-Paul C. Grund et al., In Eastern Connecticut, !DUs Purchase Syringes from
Pharmacies but Don't Corry Syringes, 10 J. ACQUIRED IMMUNE DEACIENCY SYNDROME & HUM.
RETROVIROLOGY 104 (1995).
91. Feldman & Biernacki, supra note 10, at 35.
92. Centers for Disease Control & Prevention, U.S. Dep't of Health & Human Services,
Syringe Exchange Programs-United States, 1994-1995,44 MORBIDITY & MORTALITYWKLY. REP.
684, 684 (1995).
93. !d.
94. ld. at 685.
95. !d.
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laws through legislative amendments or judicial construction, state administrative
action, or operation in a state with no such laws; and 17% operated without a
legal foundation, subject to prosecution under drug paraphernalia or prescription
laws. 96
Self-reported data likely underestimate the number of SEPs that operate
without legal sanction. Public health officials or community activists who
operate SEPs patently know that the needles and syringes they distribute will be
used to inject illicit drugs. Strictly speaking, these persons have formed the
requisite "intent" under drug paraphernalia laws and, absent some overriding
legal authority, appear to be operating illegally. Law enforcement may benignly
choose to see no "intent" under drug paraphernalia laws, but in those states with
syringe prescription laws, public health officials or community activists are
plainly engaging in unlawful behavior by distributing syringes without a medical
prescription. Thus, federal, state, or municipal police have jurisdiction to arrest
persons who participate in SEPs and attorneys general are authorized to seek an
injunction against the program. At the very least, the uncertain legal status of
some SEPs may discourage IDUs from participating in the programs.

B. Restrictions on the Use of Federal Funds for Syringe Exchange
Federal funding of SEPs is restricted to some degree in almost all
programs. Since 1988, Congress has enacted at least seven statutes that contain
provisions prohibiting or restricting the use of federal funds for syringe
exchange programs and activities. 97 The ban applies regardless of the
lawfulness of the SEP. For some time, annual federal appropriations statutes
have contained restrictions for funding SEPs. For example, Title V, Section
505 of the Fiscal 1996 Appropriations for the Departments of Labor, Health and
Human Services (DHHS), and Education provides:
[N]o funds appropriated under this act shall be used to carry out any
program of distributing sterile needles for the hypodermic injection of
any illegal drug unless the Secretary of Health and Human Services
determines that such programs are effective in preventing the spread
of HIV and do not encourage the use of illegal drugs. 98

96. Scott Burris et al., The Legal Strategies Used in Operating Syringe Exchange Programs in
the United States, 86 AM. I. PuB. HEALTH 1161, 1162 (1996).
97. U.S. GENERAL ACCOUNTING OFFICE, NEEDLE EXCHANGE PROGRAMS: REsEARCH
SUOOESfS PROMISE AS AN AIDS PREVENTION STRATEGY 25-26 (Report No. GAO/HRD-93-60
1993) [hereinafter U.S. GAO].
98. Pub. L. No. 104-134, § 505, 110 Stat. 1321 (1996). In fiscal year 1996, !his language was
included in some, but not all, continuing resolutions of agencies operating under !he purview of !he
Department of Health and Human Services (DHHS). For example, !he language did not appear in
!he continuing resolutions for !he Centers for Disease Control and Prevention and !he National
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The United States General Accounting Office concluded that the Department of
Health and Human Services (DHSS) is authorized to conduct demonstration and
research projects involving the provision of syringes, but is prohibited from
using certain funds to support SEPs directly, 99 which may prevent DHSS from
funding ancillary support services provided by SEPs. 100 According~y, SEPs
must rely exclusively on state, local, or philanthropic funds for their operational
activities, which is problematic given their uncertain legal status.
Under current law, before the federal government can fund SEPs, the
Secretary of Health and Human Services must find that the programs effectively
prevent the spread of HIV and do not encourage the use of illegal drugs. 101
The Institute of Medicine recently recommended that the Surgeon General make
the determination that the federal law bas deemed necessary before the present
prohibition against federal funds to support SEPs may be rescinded. 102
Congress, however, insists that the research additionally show that SEPs reduce
injecting drug use. 103 Although some studies suggest that this is the case, 104
the current Congress remains reluctant to fund syringe exchanges.

C. Evaluation of Syringe Exchange Programs
Research studies of SEPs, while complicated, have identified three health
benefits among IDUs who participate in these programs: reduction in high risk
behavior; reduction in the incidence of HIV and other blood-borne infections;
and greater access to drug treatment and other drug and HIV prevention
services. Each of these indicators demonstrates the potentially powerful efficacy
of SEPs.
1. Reduction in Risk-Behaviors
In studying SEPs, researchers have focused on reported changes in behavior
capable of transmitting HIV among SEP clients. Comparisons of IDUs'
reported behavior pre- and post-participation in the SEP have consistently
revealed a marked decline in the frequency of unsafe drug injection practices.
The data show that participants in SEPs are less likely to share injection

Institute of Health. Congress likely created an unintended loophole, however, and actually intended
that all funds from DHHS be subject to the quoted restriction.
99. U.S. GAO, supra note 97, at 13.
100. ld.
101. Pub. L. No. 104-134, § 505, 110 Stat. 1321 (1996).
102. NATIONAL REsEARCH COUNCIL, PREVENTING HIV, supra note 1, at 253.
103. Paula Span, Needle Exchanges Inject Controversy in AIDS Prevention, WASH. POST, July
16, 1996, at Al.
104. See U.S. GAO, supra note 97, atS-9 (discussing a number of studies showing a reduction
in drug injection among long-term SEP participants).
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equipment and more likely to use a new, sterile syringe for each injection as
recommended by public health officials. These results have been reported
among SEP participants in several cities, including New York, 105
Portland, 106 Hartford, 107 and Tacoma. 108
2. Reduction in Incidences of Blood-Borne Infections
Through a variety of direct and indirect means, scientific investigations
have shown reduced incidences of HIV infection among SEP participants.
Recent studies, described in the National Research Council's review of
SEPs, 109 found direct evidence of substantially lower rates of new HIV
infections among New York City IDUs who used SEPs.
Researchers have found indirect evidence of a reduced incidence of HIV
infection among SEP participants in Tacoma, Washington and New Haven,
Connecticut. The program in Tacoma, founded in 1988, is the longest-operating
legally-authorized SEP in the United States. 110 Studies assessing the impact
of Tacoma's SEP are significant; syringe exchange was the area's primary HIV
prevention effort, so the results of efficacy studies are less likely to be
confounded by other measures. Scientific investigations of the program also
afford comparison of reported effects across studies. Blinded seroprevalence
surveys of persons in the Tacoma area who entered drug treatment progt:ams
from June, 1988 through December, 1992 revealed an HIV seroprevalence of
2% to 4% during each year of the five-year period studied. 111 For a
community to maintain a low level of HIV infection among IDUs in the absence
of effective HIV prevention efforts is unusual. During the same period, many
geographic areas experienced a rapid rise in seroprevalence, particularly where

105. Denise Paone et al., National Research Council & Institute of Medicine, New York City
Syringe Exchange: An Overview, in WORKSHOP ON NEEDLE EXCHANGE AND BLEACH DISfRIBUTION
PROGRAMS 47 (1994).
106. Kathy Oliver et al., National Research Council & Institute of Medicine, Behavioral and
Community Impact of the Ponland Syringe Exchange Program, in WORKSHOP ON NEEDLE
EXCHANGE AND BLEACH DISfRIBUTION PROGRAMS 35 (1994).
107. Merrill Singer et al., Sale and Exchange of Syringes, 10 J. ACQUIRED IMMUNE
DEACIENCY SYNDROME & HUM. RETROVIROLOGY 104 (1995).
108. See Hollis C. Hagan et al., National Research Council & Institute of Medicine, Risk for
Human Immunodeficiency Virus and Hepatitis B Virus in Users of the Tacoma Syringe Exchange
Program, in WORKSHOP ON NEEDLE EXCHANGE AND BLEACH DISTRIBUTION PROGRAMS 24-34
(1994); Hollis C. Hagan et al., An Interview Study of Panicipants in the Tacoma, Washington,
Syringe Exchange, 88 ADDicriON 1691 (1993).
109. See generally NATIONAL REsEARCH COUNCIL, PREVENTING HIV, supra note 1.
110. /d. at 234.
Ill. See HOLLIS C. HAGAN & C.B. HALE, HIV-1 SEROPREVALENCE SURVEYS IN PIERCE
COUNTY (1993) (on file with author).
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HIV prevention efforts were not targeted at IDUs. 112 Although a sustained
low level of infection cannot be associated conclusively with syringe exchange
efforts, the data provide indirect evidence that the SEP may have prevented
some cases of HIV and that the program was not associated with an increase in
new infections. In New Haven, researchers quantified the estimated reduction
in HIV incidence based on a mathematical model of exchanged syringes
contaminated with HIV. They concluded that the New Haven SEP was
associated with a 33% reduction in HIV incidence. 113
Due to the difficulty of measuring substantial changes in new HIV
infections directly, investigators have examined changes in the incidence of other
blood-borne diseases. A case-control study conducted from 1991 through 1993
in Pierce County, Washington found that cases of both hepatitis B virus (HBV)
and hepatitis C virus (HCV) occurred significantly less frequently among SEP
participants than among the control subjects. 114 The National Research
Council concluded that "case-control studies indicate a powerful retardant effect
of needle exchange program attendance on infection with two blood-borne viral
infections. . . . "m Observational studies in Pierce County reinforce this
conclusion; new HBV and HCV cases attributable to injection drug use declined
by more than 75% within two years after a SEP was established.ll 6 During
the same time period, new cases attributable to sexual transmission remained
relatively stable. 117 The National Academy of Sciences has observed that each
of these scientific studies is methodologically flawed. Nevertheless, when
examined as a body of scientific evidence, these data are compelling. "The
situation resembles the exploration of the relationship between cigarette smoking
and lung cancer; virtually every individual study was vulnerable to some
particular objection, yet collectively those studies justified a compelling conclusion." 118

112. For example, HIV seroprevalence among IDUs in New York City increased from less than
10% to more than 50% in five years; in Edinburgh, from 0% to more than 40% in one year; in
Bangkok, from 2% to more than 40% in two years; and in Manipur, India, from 0% to 50% in one
year. Don C. DesJarlais et al., Maintaining Low HN Seroprevalence in Populations of Injecting
Drug Users, 274 JAMA 1226 (1995).
113. Edward H. Kaplan & Elaine O'Keefe, Let the Needles Do the Talking! Evaluating the
New Haven Needle Exchange, 23 INTERFACES 7 (1993).
114. After adjusting for gender, race, age, and duration of injection, the odds ratio for the
association between non-use of the exchange and hepatitis B was 5.5 (95% C.I. 1.5-20.4), while the
odds ratio for hepatitis C was 7.3 (95% C.l. 1.6-32.8). See Holly Hagan et al., Reduced Risk of
Hepatitis Band Hepatitis C Among Injection Drug Users in the Tacoma Syringe Exchange Program,
85 AM. J. PUB. HEALTH 1531 (1994).
115. NATIONAL RESEARCH COUNCIL, PREVENTING HIV, supra note 1, at 243.
116. See Miriam J. Alter et al., Risk Factors for Acute Non-A, Non-B Hepatitis in the United
States and Association with Hepatitis C Virus Infection, 264 JAMA 2231 (1990); Miriam J. Alter
et al., The Changing Epidemiology of Hepatitis Bin the United States, 263 JAMA 1218 (1990).
117. HAGAN & HALE, supra note 111.
118. NATIONAL RESEARCH COUNCIL, PREVENTING HIV, supra note I, at 3.
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3. Access to Drug Treatment and Other Drug and HIV Prevention Services
Research has demonstrated that participants in SEPs have greater access to
drug treatment and other HIV and drug prevention services. 119 The majority
of SEPs in the United States provide referrals to drug treatment; a much smaller
number offer drug treatment on-site. 120 Since drug treatment can be effective
in reducing use and dependence on illicit drugs, 121 SEPs can serve to reduce
harms from both drug use and blood-borne disease.
4. Absence of Evidence of Increased Drug Use
Law enforcement authorities and church and minority leaders often oppose
SEPs due to continuing concerns about the potential recruitment of new drug
users, apprehension of increased drug use among current IDUs, and worry about
the adverse effects on communities, including a proliferation of discarded
syringes. 122 These fears pose substantial barriers to a local community's
acceptance of SEPs. Studies of SEPs, however, have found no scientifically
reliable evidence of these negative effects.
A recurrent objection to SEPs is that easy access to clean syringes will
encourage persons to begin injecting. 123 Earlier studies found no evidence that
new injectors were entering SEPs (on average, SEP participants were older and
had been injecting longer than other IDUs in the community), 124 but the data
were not strong enough to exclude the possibility that, over time, SEPs could
increase rates of community drug use. Newer data are more conclusive. After
reviewing recent studies from both the United States and Amsterdam, the
National Research Council has found no evidence to suggest that new injectors

119. PETER LURIE ET AL., 1 THE PUBUC HEALTH IMPACT OF NEEDLE EXCHANGE PROGRAMS
IN THE UNITED STATES AND ABROAD 234-38 (1993).
120. /d. at 236-37.
121. 4 THE EFFECfiVENESS OF DRUG ABUSE TREATMENT: EVALUATION OF TREATMENT
O!ITCOMES FOR 1971-1972 DARP ADMISSION COHORT (S. Sells & D. Simpson eds., 1976); D.
Dwayne Simpson, U.S. Dep't of Health & Human Services, National Treatment System Evaluation
Based on the Drug Abuse Reporting Program (DARP) Follow Up Research, in DRUG ABUSE
TREATMENT EVALUATION: STRATEGIES, PROGRESS AND PROSPECTS 29, 36 (1984).
122. Minority communities and church groups in poor inner city areas are particularly vehement
in their opposition to clean-needle programs; the disparate impact that drug use has on their
communities fuels fears that they will bear the risk of experimental needle exchange programs.
Hanna Rosin, Hiding from a Killer, Denial and Paranoia- "it's a Plot by the White Man • -May Be
Fueling the Spread of AIDS in the Black Community, ATI.ANTA I. & CONST., July 2, 1995, at Bl.
See also Council Calls for End to Free-Needles Plan, N.Y. nMES, Dec. 7, 1988, at B10; Michael
Marriott, Needle Exchange Angers Many Minorities, N.Y. nMES, Nov. 7, 1988, at Bl.
123. FRANKLIN E. ZIMRING & GoRDON HOPKINS, THE SEARCH FOR RATIONAL DRUG
CONTROL 171 (1992).
124. LURIE ET AL., supra note 119, at 275.
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are being recruited through access to syringes from SEPs. Even in Amsterdam,
where SEPs serve both injecting and non-injecting drug users, results reveal no
changes in the proportion of the two groups of users: 125
Critics also argue that SEPs might increase drug use among existing IDUs.
The evidence suggests that this danger is unlikely. Drug use is driven by
physiological and psychological dependency, as well as by the availability of the
drug itself rather than the means to administer it. An increase in sterile injection
equipment will likely have little impact on the level of drug use; IDUs who
procure drugs but lack access to new injection equipment simply re-use old
needles and syringes. The most recent studies in New York, San Francisco, and
Portland report either stable levels of injection, 126 or decreased rates of
injection among SEP participants. 127
A fmal objection to SEPs is based on the environmental and health hazards
of contaminated syringes. Where the problem has been systematically studied,
no evidence has been found that SEPs cause an increase in the total number of
discarded syringes; they may in fact result in fewer improperly discarded
syringes. 128 Many progr31I1S employ a one-for-one exchange, which motivates
IDUs to return used syringes and produces no net increase in the number of
syringes in circulation. 129
In summary, a great deal of evidence exists that SEPs are effective
interventions for prevention of HIV and other blood-borne diseases. They
provide IDUs with the means to protect their own health, promote safer drug
injection practices, and reduce or stabilize the rates of blood-borne infection.
Moreover, SEPs provide these benefits with little economic cost and with no
observable adverse effects on society's attempts to decrease drug dependency.

125. NATIONAL REsEARCH COUNOL, PREVENTING AIDS, supra note 1, at 225-26.
126. John K. Watters eta!., Syringe and Needle-Exchange as HIV/AIDS Prevention for Injection
Drug Users, 271 JAMA 115 (1994).
127. See generally NATIONAL REsEARCH COUNOL, PREVENTING AIDS, supra note 1. The only
recent srudy to show an increase is unpublished.
128. LURIE ET AL., supra note 119.
129. Merrill Singer et al., Sale and Exchange of Syringes, 10 J. ACQUIRED IMMUNE
DEACIENCY SYNDROME & HUM. RETROVIROLOGY 104 (1995) (reporting about one-to-one syringe
exchanges).
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PROVIDING TREATMENT TO REDUCE THE INTERCONNECTED
EPIDEMICS OF DRUG USE AND BLOOD-BORNE DISEASE

The foregoing public health strategies are designed to make drug injection
safer for individuals who cannot or will not stop using illicit drugs. The
rationale for these interventions is not necessarily that drug use is legitimate
from a moral, legal, or public health perspective. Rather, the social imperative
of reducing the considerable morbidity and premature mortality associated with
drug injection justifies these strategies. Society cannot ethically stand by and
accept profound health consequences for drug users, their sexual partners, and
children, when these consequences are largely preventable at a reasonable cost.
Public health strategies do not merely strive to make drug injection safer,
but also to reduce drug use itself. Since drug use results in significant harms
to the physical and mental health of the individual, and since it results in
violence and family disintegration in the community, public health strategies
must embrace interventions designed to help individuals to stop using illicit
drugs. Reducing injecting drug use is the single most effective means of
preventing the transmission of blood-borne diseases.
One of the most promising strategies for reducing drug use is to provide
treatment. Yet, there exists a distinct ambivalence toward drug treatment in the
United States. While drug use is considered an overarching social problem, 130
relatively few resources are devoted to treatment. The percentage of the federal
drug budget devoted to treatment pales in comparison with funds allocated for
law enforcement and interdiction. 131 There are long waiting lists for drug
treatment programs throughout the United States. 132
Delays in providing treatment for IDUs cost human lives and scarce health
care resources. An IOU who is turned away from treatment will in all
probability continue the dangerous cycle of drug use, sharing of injection
equipment, crime, and imprisonment. Neither imprisonment nor hospitalization

130. See BUREAU OF JUSflCE STATISflCS, U.S. DEP'T OF JUsnCE, A NATIONAL REPORT:
DRUGS, CRIME, AND THE JUSflCE SYSTEM 93 (1992) (reporting that 60% of the population in 1989
perceived drugs as one of the factors most responsible for crime in the United States). ·
131. See, e.g., Roberto Suro, Drug Control StraJegy in Midst of a Makeover: Problem Is
Recast as Public Health Issue, WASH. POST, Mar. 2, 1997, at All (estimating federal funding for
drug control enforcement at over $7.75 billion in 1996, with comparable federal funding for
treatment and prevention during the same year estimated at $4.0 billion).
132. See, e.g., Lawrence 0. Gostin, The Interconnected Epidemics of Drug Dependency and
AIDS, 26 HARV. C.R.-C.L. L. REV. 113, 173-75 (1991) (citing NATIONAL ASS'N OF STATE
ALCOHOL AND DRUG ABUSE DIRECTORS, TREATMENT WORKS: A REVIEW OF 15 YEARS OF
REsEARCH FINDINGS ON ALCOHOL AND OTHER DRUG ABUSE TREATMENT OUTCOMES (1990)
[hereinafter TREATMENT WORKS]).
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for drug-associated illnesses addresses the problem; when the user is released
from prison or the hospital, the cycle will likely repeat itself. The result is an
ever increasing spiral of drug use, crime, and blood-borne infection. The
lifestyles of drug dependent people often drive them to seek immediate relief
from the physical and psychological effects of drugs. A user cannot be relied
upon to reappear for a treatment slot that becomes available at some future time.
Moreover, society may have lost any opportunity to get the user into treatment.
For these reasons, the comprehensive goal of public health must be drug
treatment on demand.
Treatment is often undervalued as a policy option because of the perception
that drug use is primarily a problem for law enforcement, rather than for public
health. 133 Part of the reason for this perception may be that drug use is
thought to result from willful behavior, rather than from a classic disease
process. More importantly, many believe that drug treatment simply does not
work. Below, I present the extant empirical data showing the striking costefficacy of drug treatment. This is followed by proposals to expand access to
drug treatment in the health care and criminal justice systems.
A. The Efficacy and Cost-Effectiveness of Treatment as a Public Health Strategy

A common view of drug dependency is that it is a chronic, relapsing illness
that is resistant to treatment. Yet, a great deal of evaluative research
demonstrates the efficacy of treatment in reducing drug use, multi-person use of
syringes, and in increasing employment and social adjustment. 134 Further, the
longer the treatment process, the more likely that it will be effective in
ameliorating the profound physical, psychological, and social problems of drug
dependency. 135
Treatment outcome data, to be sure, are compromised by the lack of
controlled clinical trials. 136 Much of the early research also focused on heroin

133. See Suro, supra note 131, at All. This perception may be changing at the urging of
President Clinton and Barry R. McCaffrey, head of the White House drug policy office. "Clinton's
[drug control] strategy represents a profound shift in rhetoric," said Kenneth Sharpe, a professor of
political science at Swarthmore College and frequent critic of federal drug policies. /d. "It is the
first significant step toward talking about illicit drug use as more of a public health issue than as a
crime problem." ld.
134. SeeNATIONALCRIMINALJUSTICEASS'N, U.S. DEP'TOFJUSTICE, TREATMENT OPTIONS
FOR DRUG-DEPENDENT OFFENDERS: A REVIEW OF THE LITERATURE FOR STATE AND LoCAL
DECISIONMAKERS 2-5 (1990).

135. See generally Lawrence 0. Gostin, Compulsory Treatment for Drug-Dependent Persons:
Justifications for a Public Health Approach to Drug Dependency, 69 MILBANK Q. 561 (1991).
136. CONGRESSIONAL OFFICE OF TECHNOLOGY ASSESSMENT, THE EFFECTIVENESS OF DRUG
ABUSE TREATMENT: IMPLICATIONS FOR CONTROLLING AIDSIHIV INFECTION 62-64 (1990).
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rather than cocaine use. Despite the methodologic concerns, authoritative
reviews of a large number of outcome studies conclude that treatment is
effective. 137 Much of the collective knowledge of treatment effectiveness
derives from two large-scale, federally funded, longitudinal studies: the
Treatment Outcome Prospective Study (TOPS) 138 and the National Treatment
System Based on the Drug Abuse Reporting Program (DARP). 139 TOPS and
DARP, together with numerous smaller studies, 140 demonstrate that three
primary treatment modalities were effective in causing significant and enduring
declines in drug use and criminal behaviors-methadone maintenance (and other
opioid substitution therapies, including the recent use of the FDA-approved,
long-acting opioid, Levo-Alpha-Acetyl-Methadol [LAAM]), 141 therapeutic
communities, and outpatient drug-free programs.
Methadone maintenance allows a short-acting opiate administered with
needles to be replaced with a legal, long-acting, safe, and orally administered
substance. 142 The Congressional Office of Technology observes that the
"consistency of the scientific literature regarding the safety, efficacy, and
effectiveness of methadone is overwhelming, yet some still consider methadone
a controversial treatment modality." 143
The Institute of Medicine has
concluded that about 25% to 45% of opiate addicts who begin methadone
maintenance treatment continue treatment for a year or longer. 144 Methadone
maintenance has the highest rate of retention of all treatment modalities, and
lowers HIV risk behavior by significantly reducing the number of injections and
sharing of equipment. 145
A study in 1993 examined the rates of AIDS risk behaviors (particularly
among IDUs) between comparable samples of opiate addicts in methadone
maintenance treatment and those who were not receiving such treatment. The

137. See id.; NATIONAL CRIMINALJUsriCE ASS'N, supra note 134; TREATMENT WORKS, supra
note 132.
138. See CONGRESSIONAL OFFICE OF TECHNOLOGY ASSESSMENT, supra note 136, at 65-86;
1 INSIITUTE OF MEDICINE, TREATING DRUG PROBLEMS (1990).
139. See OPIOID ADDICTION AND TREATMENT: A 12 YEAR FOLLOW UP (D.D. Simpson & S.B.
Sells eds., 1990).
140. See A. Thomas McLellan et al., Is Treatment for Substance Abuse Effective?, 247 JAMA
1423 (1982); NATIONAL INSfiTUTE ON DRUG ABUSE, REsEARCH AND CLINICAL PRACTICE (1983).
141. JANICE FAY KAUFFMAN & GEORGE E. WOODY, U.S. DEP'T OF HEALTH AND HUMAN
SERVICES, MATCHING TREATMENT TO PATIENT NEEDS IN OPIOID SUBsriTUTION THERAPY 6 ( 1995).
142. /d. at 62.
143. CONGRESSIONAL OFFICE OF TECHNOLOGY AssESSMENT, supra note 136, at 76. See also
KAUFFMAN & WOODY, supra note 141, at 7 ("Ambivalence about opioid substitution therapy
continues in spite of the overwhelming scientific evidence of its effectiveness.").
144. INSTITUTE OF MEDICINE, FEDERAL REGULATION OFMETHADONETREATMENT22 (1995).
145. James R. Cooper, Methadone Treatment and Acquired Immunodeficiency Syndrome, 262
JAMA 1664 (1989).
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results of this comprehensive study are remarkable. At baseline, 13% of the
methadone-maintained group were HIV positive compared to 21% of those not
on treatment. Over the course of three years, an additional 5% of the
methadone-maintained group became infected with HIV (all of which had
dropped out of their treatment program), while an additional 26% of those not
on treatment at baseline became infected. 146 Although this study does not
prove that methadone treatment was the causal agent between the different rates
of infection, it suggests that participation in the treatment program was a factor
in reducing AIDS risk behaviors. 147 Although several pharmacotherapies are
currently being evaluated, the absence of any established efficacious agent is
having dire consequences for cocaine-dependent persons and, if they are HIV
infected, their sexual partners.
Therapeutic communities are "residential programs with expected stays of
nine to twelve months, phasing into independent residence. " 148 Therapeutic
community clients end virtually all illicit drug taking and other criminal behavior
while in residence and perform better than those not in treatment (in terms of
reduced drug use and criminal activity and increased social productivity) after
discharge. 149
Outpatient drug-free programs display a great deal of heterogeneity, and
range from one-time assessments and drop-in, or "rap" centers to virtual
outpatient therapeutic communities with daily psychotherapy and counseling.
The TOPS and DARP studies suggest similarly favorable outcomes for drug
users attending outpatient drug-free programs. 150
Yet, evaluation is
significantly hampered by the lack of uniformity in these programs and the small
number of clients.
The evidence suggests that drug treatment is not only efficacious, it is cost
effective. Comprehensive cost/benefit analyses conducted by the TOPS 151
study and another report in California, the Tabbush 152 study, conclude that
state level funding of drug abuse programs is economically justified. The
studies focus on societal savings and benefits realized from: reduced arrest,
prosecution, and incarceration costs; reduced loss due to property theft; reduced
social costs due to an improved labor market; and reduced medical treatment

146.
147.
148.
149.
150.
151.
152.

INSTITUTE OF MEDICINE, supra note 144, at 23-24.
/d. at 24.
1 INSTITUTE OF MEDICINE, supra note 138, at 14.
/d. at 188-89.
CONGRESSIONAL 0FACE OF TECHNOLOGY AssESSMENT,

supra

note 136, at 84-86.

Id. at 65-86.

VICTOR TABBUSH, THE EFFECTIVENESS AND EFACIENCY OF PUBUCLY FuNDED DRUG
ABUSE TREATMENT AND PREvENTION PROGRAMS IN CALIFORNIA: A BENEFIT Cosr ANALYSIS

(1986).
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costs. The TOPS study concludes that there was an 11% to 30% decline in these
indirect costs as a consequence of drug abuse treatment. The Tabbush study
found a benefit-cost ratio of 1 to 11.54-for every dollar spent for effective drug
treatment, $11. 54 of social costs is saved. 153
If policy makers concur that prevention and treatment-when properly
designed, funded, and executed-are beneficial to the individual and are cost
effective, the remaining question is how best to reach the drug user to reduce
demand. A fundamental problem with existing treatment services is that they
are often far removed from the silent world of the illicit drug user. Virtually
all treatment services are delivered through traditional drug treatment facilities
separated from the mainstream health care system. Drug treatment occurs, if
at all, when a drug user seeks out services, has the persistence to wait his tum
on the list, and voluntarily remains in treatment for the duration necessary to
obtain results. This system is, at best, haphazard and idiosyncratic. At worst,
it perpetuates the revolving door between drug use, needle sharing, and brief
stays in detoxification or in prison.

The lesson for policy makers from the social science research is therefore
relatively simple. The most effective strategy to reduce the dual epidemics of
drug use and blood-borne disease is to identify as many unrecognized cases as
possible and to give them the opportunity to enter and remain in treatment for
durations that maximize the chance of a positive outcome. Two distinct loci for
enhancing the capacity to identify and treat drug dependent persons are the
health care and criminal justice systems. Large numbers of otherwise
unrecognized and untreated drug users come into contact with both systems. It
makes no sense to have a seriously drug-dependent person pass through an
emergency room, hospital, courtroom, or prison and fail to identify her as a
person who needs treatment.
B. Treatment of Drug-Dependent Persons in the Health Care System

Seriously drug-dependent people are likely to have multiple health
problems, not only because of the physical and psychological effects of their
dependency, but because they are likely to be poor, malnourished, even
homeless. As a result of their multiple health problems, drug-dependent persons
are likely to come into contact with the health care system in traditional venues
such as hospitals, emergency rooms, community health and mental health
centers, family physician offices, managed care organizations, and the like.

153. /d. at 94.
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Patients with drug-related illness form a major proportion of hospital,
particularly emergency department, admissions in the United States. 154
Hospitals participating in the Drug Abuse Warning Network (DAWN) in twentyone American cities reported in 1990 that over one-half of their approximately
371,000 emergency room episodes involved illegal drug use. 155 Thousands of
other unidentified drug users, many already HIV positive, pass through the
health care system. Blinded studies of sentinel hospitals throughout the United
States suggest that as many as 80,000 cases of HIV infection pass undetected
through American hospitals each year. 156 A large proportion of these cases
are likely to be unrecognized and untreated injecting drug users.
Even if seriously drug-dependent people were identified in traditional health
care settings, they would be unlikely to receive the expert care needed to
ameliorate their long-term dependencies. Traditional medicine is ill-prepared,
at the most fundamental levels, to provide effective drug abuse treatment. 157
Research shows that medical school training in drug abuse treatment is quite
poor. Medical education, from internship through residency, rarely exposes
medical students to addicts and the problems of drug dependency. Even primary
care physicians themselves feel they are incompetent to treat substance abuse,
and research supports their beliefs that they are inaccurate in identifying and
diagnosing substance abuse. 158
The inadequate medical education, and the poor attitudes toward drug users
among physicians, are not the only problems in providing drug treatment
services in the mainstream health care system. Physicians in most mainstream
health care settings cannot legally prescribe methadone-the FDA approved
chemical treatment for opiate abuse. Prescribing methadone has, from its
inception, been highly regulated. 159 There are strict conditions for its use. 160
In particular, a provider cannot prescribe methadone unless she is specifically

154. THE WHITE HOUSE, NATIONAL DRUG CONTROL STRATEGY 3 (1989).
155. BUREAU OF JUSTICE STATISTICS, supra note 130, at 11. Cocaine topped the list at
approximately 125,000 emergency room episodes in 1990. ld. Heroin/morphine use resulted in
slightly less than 50,000 episodes in 1990, with reported instances of marijuana, PCP, and
barbiturates use totaling less than 25,000 each in the same year. ld.
156. See Michael E. St. Louis eta!., Seroprevalence Rates of Human Immunodeficiency Virus
Infection at Sentinel Hospitals in the United States, 323 NEW ENG. J. MED. 213 (1990).
157. The Drug Policy Research Center aptly observes that drug treatment has been deemphasized by the health care industry because the "mechanisms for funding drug treatment and the
institutions that provide treatment have developed quite separately from the regular system of health
care in America. . . . " JOHN G. HAAGA & ELIZABETII A. MCGLYNN, THE DRUG ABUSE
TREATMENT SYSTEM, PROSPECTS FOR REFORM 1 (1993).
158. See Chemical Dependency: A Treatable Disease, 81 OHIO ST. MED. J. 77 (1985).
159. See INSTITUTE OF MEDICINE, FEDERAL REGULATION OF METIIADONE TREATMENT 120-50
(1995).
160. See 21 C.F.R. §§ 291.501-.505 (1996).
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approved for the purpose, and approval is not granted unless there is compliance
with detailed regulations concerning staff-patient ratios, counseling, and
paperwork. 161 The regulations have had the effects of stifling growth of
methadone treatment and discouraging ordinary health care providers from
offering drug abuse treatment at all.
Consider the typical case of a seriously drug dependent person in an
emergency department or hospital bed. The health care professional can treat
all of the physical conditions associated with drug use, but is unable to prescribe
treatment related to the primary ·diagnosis of drug dependency.
The
professional's only realistic option, assuming the drug problem is even
diagnosed, is to place the patient on a waiting list for a drug treatment slot, with
all of the known limitations of a waiting list placement.
Thus, although drug dependent people are in routine contact with the health
care system, which has the unique capacity to identify and care for patients,
systemic problems remain in utilizing the mainstream health care system for
these purposes. Integration of drug treatment into primary care, hospitals,
community health and mental health centers, managed care organizations, and
other providers will require a sizable influx of resources for training, facilities,
and staff. It may also require fundamental reform of federal regulations to
allow physicians to prescribe methadone and future chemical treatments for drug
dependency.
C. Treatment of Drug Dependent Persons in the Criminal Justice System

Drug abuse is placing an extraordinary burden on law enforcement, courts,
and prisons. 162 Considerable evidence exists showing the close relationship
between drug use and crime. Voluntary urine tests taken of arrestees in twentythree major cities in 1993 revealed that on average more than 50% of those
tested had used drugs recently and 75% of inmates report using drugs during
their lifetimes. 163 The Department of Justice reported in 1992 that more than
half of violent offenders in state prisons committed their offenses under the
influence of illicit drugs. 164 An inordinately high proportion of persons
arrested for criminal offenses in the United States have recently used drugs,
including injection drugs such as heroin. One study reported that one-third of
state prison inmates who used drugs in the past utilized a needle and syringe to

161. /d. § 291.505(b)(2)-(4). See also lNsnTUTE OF MEDICINE, supra note 159, at 120-50.
162. See BUREAU OF JUsriCE STATisriCS, U.S. DEP'T OF JUsriCE, DRUGS AND CRIME
FACTs-1994, at 10-15 (1995).
163. /d. at6-7.
164. BUREAU OF JUsriCE STATisriCS, supra note 130, at 5.
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inject drugs; 15% of these same inmates reported sharing a needle at least
once. 16S Prisoners also sometimes continue drug use after incarceration, and
may even share injection equipment with other prisoners. 166 Despite the large
number of drug dependent persons coming into contact with the criminal justice
system, there are few comprehensive treatment programs. Surveys suggest that
very few prison inmates receive treatment, and many of the nation's prisons
have no identifiable drug abuse treatment program. 167 For many in the
criminal justice system, routine urine testing is the only "treatment" provided.
The criminal justice system, particularly in corrections, often presents
ideological, economic, and practical reasons for not providing treatment for
more people. This resistance to establishing effective drug treatment programs
reflects once again the tension between the preventive and punitive goals of
criminal justice and rehabilitation. Even if this conflict could be solved, severe
prison overcrowding and limited resources make the provision of treatment
difficult.
The ideological aversion to rehabilitation is not a serious argument against
sufficient and adequate treatment in the corrections system. Rather, it is a mere
abstraction fueled by the government's policy of holding users accountable or
punishing them. There are budgetary and practical restraints on treatment
expansion in prisons. However, financial analyses continually show that
treatment is highly cost effective. 168 Planners should carefully consider the
future savings associated with effective treatment when attempting to work
within present budgetary constraints.
Systematic treatment of persons in the criminal justice system is fully
consistent with the research presented earlier. Criminal justice settings
(including diversion, probation, prison and parole) provide optimal opportunities
for treatment: large numbers of drug users come into contact with these
programs; they are captive participants who otherwise often have unproductive
time; they are already subject to state control because of their offenses; and they
may remain under control for considerable periods, thereby providing the best
opportunity for successful treatment outcomes. A demand reduction model,
based on sound public health principles and practices, works better, is more
humane, and costs less than the model of punishment and retribution that has
dominated government thinking.

165. BUREAU OF JUSTICE STATISTICS, supra note 162, at 7.
166. See G.L. Vigdal & D.W. Stadler, Controlling Inmate Drug Use Cut Consumption by
Reducing Demand, CORRECTIONS TODAY, June 1989, at 97 (before intervention, 26.9% of inmate
urine samples tested positive for illicit drugs).
167. FRANK nMS, DRUG ABUSE TREATMENT IN PRISON 13 (National Institute on Drug Abuse
Research Report No. ADM 86-1149, 1981).
168. See supra notes 134-53 and accompanying text.
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CONCLUSION

The interconnected epidemics of injecting drug use and blood-borne disease
cause illness and death among drug users, their sexual partners, and children.
Permitting the profound adverse health effects would be conscionable if science
and public health could not provide cost effective methods to reduce morbidity
and premature mortality without significant tradeoffs. However, there exists a
great deal of accumulated evidence that a public health approach could markedly
improve the health of large populations by reducing blood-borne disease,
including HIVI AIDS, and reducing the harms of drug use itself.
A comprehensive, well-fmanced public health strategy to impede the dual
epidemics of drug use and HIV I AIDS includes: deregulation of syringe
possession and distribution; expansion of syringe exchange programs, including
an end to the ban on federal funding; increased access to high quality treatment
for drug and alcohol dependency, particularly in the health care and criminal
justice systems; education and counseling regarding drug abuse and blood-borne
disease; and support and community activities for families and young
people. 169
Far from "sending the wrong message" or encouraging initiation into drug
use, a public health approach would reduce drug use while still averting harms
to individuals who cannot or will not stop taking drugs. The evidence suggests
that a public health approach should reduce morbidity and mortality associated
with blood-borne disease, and can be implemented without harmful social or
economic repercussions. A public health approach does not itself increase the
availability of illicit drugs, and is not equivalent to condoning drug use.
Ultimately, both law enforcement and public health should seek the same
end-to promote the health and safety of the population through a comprehensive
program designed to prevent drug dependency and blood-borne disease.

169. NATIONAL COMMISSION ON AIDS, THE TwiN EPIDEMICS OF SUBSTANCE USE AND HIV
(1991).
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